

Pipeline

19 targets supported by GENETIC VALIDATION

The industry's largest toolkit with **11** MODALITIES*

A mix of **INNOVATIVE MOLECULES, NEW INDICATIONS, AND BIOSIMILARS**

A robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illness. Amgen is focused on high-quality candidates that demonstrate large, clinically-relevant effects. Human genetic validation is used whenever possible to enhance the likelihood of success.

PHASE ONE			PHASE TWO			PHASE THREE		
AMG 172 Hematology/ Oncology	AMG 208 Hematology/ Oncology	AMG 211 Hematology/ Oncology	AMG 139 Inflammation	AMG 157 Inflammation	AMG 181 Inflammation	AMG 334 Neuroscience	Aranesp® (darbepoetin alfa) Hematology/ Oncology	BLINCYTO® (blinatumomab) Hematology/ Oncology
AMG 228 Hematology/ Oncology	AMG 232 Hematology/ Oncology	AMG 282 Inflammation	AMG 334 Neuroscience	AMG 337 Hematology/ Oncology	AMG 899 (TA-8995) Cardiovascular	Etelcalcetide (AMG 416) Nephrology	IMLYGIC™ (talimogene laherparepvec) Hematology/ Oncology	Kyprolis® (carfilzomib) Hematology/ Oncology
AMG 301 Neuroscience	AMG 319 Hematology/ Oncology	AMG 330 Hematology/ Oncology	BLINCYTO® (blinatumomab) Hematology/ Oncology	Kyprolis® (carfilzomib) Hematology/ Oncology	Omecamtiv mecarbil Cardiovascular	Prolia® (denosumab) Bone Health	Repatha® (evolocumab) Cardiovascular	Romosozumab Bone Health
AMG 357 Inflammation	AMG 557 Inflammation	AMG 581 Neuroscience	XGEVA® (denosumab) Hematology/ Oncology			Trebananib Hematology/ Oncology	Vectibix® (panitumumab) Hematology/ Oncology	XGEVA® (denosumab) Hematology/ Oncology
AMG 595 Hematology/ Oncology	AMG 780 Hematology/ Oncology	AMG 811 Inflammation						
AMG 820 Hematology/ Oncology	AMG 876 Metabolic Disorders	AMG 900 Hematology/ Oncology						
Oprozomib Hematology/ Oncology								

BIOSIMILARS[‡]

ABP 501 (biosimilar adalimumab) Inflammation	ABP 710 (biosimilar infliximab) Inflammation	ABP 980 (biosimilar trastuzumab) Hematology/ Oncology	ABP 494 (biosimilar cetuximab) Hematology/ Oncology	ABP 215 (biosimilar bevacizumab) Hematology/ Oncology	ABP 798 (biosimilar rituximab) Hematology/ Oncology & Inflammation
---	---	---	---	---	---

* Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
[‡]Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of November 2, 2015. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

PHASE ONE Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects.			
MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
AMG 172	Antibody-Drug Conjugate	Hematology/Oncology	AMG 172 is a human anti-CD27L antibody-drug conjugate. It is being investigated in renal cell carcinoma.
AMG 208	Small Molecule	Hematology/Oncology	AMG 208 is a small molecule inhibitor of MET. It is being investigated as a cancer treatment.
AMG 211	BiTE [®] Antibody	Hematology/Oncology	AMG 211 is an anti-CEA x anti-CD3 (BiTE [®]) bispecific antibody construct. It is being investigated as a cancer treatment in solid tumors. AMG 211 is being jointly developed in collaboration with MedImmune.
AMG 228	Monoclonal Antibody	Hematology/Oncology	AMG 228 is a monoclonal antibody being investigated for the treatment of solid tumors.
AMG 232	Small Molecule	Hematology/Oncology	AMG 232 is a small molecule inhibitor of MDM2. It is being investigated as a cancer treatment.
AMG 282	Monoclonal Antibody	Inflammation	AMG 282 is a human antibody that inhibits binding of interleukin-33 to the ST2 receptor. It is being investigated as a treatment for asthma.
AMG 301	Monoclonal Antibody	Neuroscience	AMG 301 is a monoclonal antibody being investigated for the treatment of migraine.
AMG 319	Small Molecule	Hematology/Oncology	AMG 319 is a small molecule inhibitor of PI3 Kinase delta. It is being investigated in hematologic malignancies.
AMG 330	Monoclonal Antibody	Hematology/Oncology	AMG 330 is an anti-CD33 x anti-CD3 (BiTE [®]) bispecific antibody. It is being investigated as a treatment for acute myeloid leukemia.
AMG 357	Small Molecule	Inflammation	AMG 357 is a small molecule. It is being investigated as a treatment for autoimmune diseases.
AMG 557	Monoclonal Antibody	Inflammation	AMG 557 is a human monoclonal antibody that inhibits the action of B7 related protein (B7RP-1). It is being investigated as a treatment for systemic lupus erythematosus. AMG 557 is being jointly developed in collaboration with AstraZeneca.
AMG 581	Small Molecule	Neuroscience	AMG 581 is a small molecule being investigated for the treatment of schizophrenia.
AMG 595	Antibody-Drug Conjugate	Hematology/Oncology	AMG 595 is a human anti-epidermal growth factor receptor variant III (anti-EGFRvIII) antibody-drug conjugate. It is being investigated as a treatment for glioblastoma.
AMG 780	Monoclonal Antibody	Hematology/Oncology	AMG 780 is a human anti-angiopoietin antibody that inhibits the interaction between the endothelial cell-selective Tie2 receptor and its ligands Ang1 and Ang2. It is being investigated as a cancer treatment.

* Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
 †Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of November 2, 2015. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

PHASE ONE Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
AMG 811	Monoclonal Antibody	Inflammation	AMG 811 is a human monoclonal antibody that inhibits interferon gamma. It is being investigated as a treatment for systemic lupus erythematosus.
AMG 820	Monoclonal Antibody	Hematology/Oncology	AMG 820 is a human monoclonal antibody that inhibits c-fms and decreases tumor-associated macrophage (TAM) function. It is being investigated as a cancer treatment.
AMG 876	Fusion Protein	Metabolic Disorders	AMG 876 is a fusion protein. It is being investigated as a treatment for type 2 diabetes
AMG 900	Small Molecule	Hematology/Oncology	AMG 900 is a small molecule inhibitor of Aurora kinases A, B, and C. It is being investigated as a cancer treatment.
Oprozomib <i>oh proz' oh mib</i>	Small Molecule	Hematology/Oncology	Oprozomib is an oral proteasome inhibitor. It is being investigated for the treatment of hematologic malignancies, with Phase 1b studies ongoing.

PHASE TWO Phase 2 clinical trials investigate side effect profiles and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
AMG 139	Monoclonal Antibody	Inflammation	AMG 139 is a human monoclonal antibody that inhibits the action of interleukin-23. It is being investigated as a treatment for Crohn's disease, with a Phase 2 study ongoing. As of April 1, 2015, Amgen has suspended participation in the co-development and commercialization of AMG 139 with AstraZeneca, with the option of resuming such participation at a later date.
AMG 157	Monoclonal Antibody	Inflammation	AMG 157 is a human monoclonal antibody that inhibits the action of TSLP. It is being investigated as a treatment for asthma, with a Phase 2 study ongoing. AMG 157 is being jointly developed in collaboration with AstraZeneca.
AMG 181	Monoclonal Antibody	Inflammation	AMG 181 is a human monoclonal antibody that inhibits the action of alpha4/beta7. It is being investigated as a treatment for ulcerative colitis and Crohn's disease, with Phase 2 studies ongoing. AMG 181 is being jointly developed in collaboration with AstraZeneca.
AMG 334	Monoclonal Antibody	Neuroscience	AMG 334 is a human monoclonal antibody that inhibits the receptor for calcitonin gene-related peptide. It is being investigated for the prevention of migraine. Phase 3 studies in episodic migraine are underway, and the Phase 2 study in chronic migraine is ongoing.
AMG 337	Small Molecule	Hematology/Oncology	AMG 337 is a small molecule inhibitor of MET. It is being investigated as a cancer treatment with a Phase 2 study for the treatment of gastric cancer ongoing.
AMG 899 (TA-8995)	Small Molecule	Cardiovascular	AMG 899 (TA-8995) is a small molecule cholesteryl ester transfer protein (CETP) inhibitor. It is being investigated for the treatment of dyslipidemia.

* Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
 ‡ Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of November 2, 2015. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

PHASE TWO Phase 2 clinical trials investigate side effect profiles and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
BLINCYTO® (blinatumomab) <i>blin' a toom' oh mab</i>	BiTE® Antibody & Oncolytic Immunotherapy	Hematology/Oncology	<p>BLINCYTO® is an anti-CD19 x anti-CD3 (BiTE®) bispecific antibody.</p> <p>A Phase 3 study in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) is ongoing. Phase 2 studies in adult patients with relapsed/refractory Philadelphia chromosome-positive (Ph+) and minimal residual disease of ALL are ongoing. A Phase 2 study in adult patients with diffuse large B-cell lymphoma (DLBCL) is ongoing.</p>
Kyprolis® (carfilzomib) <i>car fil' zoe mib</i>	Small Molecule	Hematology/Oncology	<p>Kyprolis® is a proteasome inhibitor.</p> <p>Amgen has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Kyprolis® to seek approval for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy based on the data from the global Phase 3 ASPIRE (Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone for the treatment of Patients with Relapsed Multiple Myeloma) trial.</p> <p>In September 2015, the U.S. Food and Drug Administration (FDA) accepted for priority review the supplemental New Drug Application of Kyprolis® for Injection for patients with relapsed multiple myeloma based on data from the ENDEAVOR (Randomized, Open Label, Phase 3 Study of Carfilzomib Plus Dexamethasone Versus Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma) trial. The FDA has set a January 22, 2016 Prescription Drug User Fee Act (PDUFA) target action date as a goal for the completion of their review of our application.</p> <p>A Phase 3 study, CLARION, evaluating Kyprolis® in combination with melphalan and prednisone compared to bortezomib, melphalan and prednisone in newly diagnosed multiple myeloma is ongoing. A Phase 3 study, ARROW, with weekly dosing in relapsed and refractory multiple myeloma is also underway.</p>
Omecamtiv mecarbil <i>om' e kam' tiv me kar' bil</i>	Small Molecule	Cardiovascular	<p>Omecamtiv mecarbil is a small molecule activator of cardiac myosin. It is being investigated for the treatment of heart failure. Amgen is developing this product in collaboration with Cytokinetics.</p>
Oprozomib <i>oh proz' oh mib</i>	Small Molecule	Hematology/Oncology	<p>Oprozomib is an oral proteasome inhibitor. It is being investigated for the treatment of hematologic malignancies, with Phase 1b studies ongoing.</p>
XGEVA® (denosumab) <i>den oh sue' mab</i>	Monoclonal Antibody	Hematology/Oncology	<p>Denosumab is a human monoclonal antibody that inhibits RANKL.</p> <p>Phase 3 studies of XGEVA® for the delay or prevention of bone metastases in patients with adjuvant breast cancer and prevention of skeletal-related events (SREs) in patients with multiple myeloma are ongoing. A Phase 2 study in non-small cell lung cancer is ongoing.</p>

PHASE THREE Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
-------------------------------	----------	------------------	-------------

* Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
 ‡ Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of November 2, 2015. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

PHASE THREE Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.			
MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
AMG 334	Monoclonal Antibody	Neuroscience	<p>AMG 334 is a human monoclonal antibody that inhibits the receptor for calcitonin gene-related peptide. It is being investigated for the prevention of migraine.</p> <p>Phase 3 studies in episodic migraine are underway, and the Phase 2 study in chronic migraine is ongoing.</p>
Aranesp® (darbepoetin alfa) <i>dar" be poe" e tin al fa</i>	Therapeutic Protein	Hematology/Oncology	<p>Aranesp® is a recombinant human protein agonist of the erythropoietin receptor.</p> <p>A Phase 3 study of Aranesp® for the treatment of low risk myelodysplastic syndromes is ongoing.</p>
BLINCYTO® (blinatumomab) <i>blin" a toom" oh mab</i>	BiTE® Antibody & Oncolytic Immunotherapy	Hematology/Oncology	<p>BLINCYTO® is an anti-CD19 x anti-CD3 (BiTE®) bispecific antibody.</p> <p>A Phase 3 study in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) is ongoing. Phase 2 studies in adult patients with relapsed/refractory Philadelphia chromosome-positive (Ph+) and minimal residual disease of ALL are ongoing. A Phase 2 study in adult patients with diffuse large B-cell lymphoma (DLBCL) is ongoing.</p>
Etelcalcetide (AMG 416) <i>e" tel kal" se tide</i>	Peptide	Nephrology	<p>Etelcalcetide (AMG 416) is a peptide agonist of the human cell surface calcium-sensing receptor (CaSR). It is being investigated as a treatment of secondary hyperparathyroidism (SHPT) that is administered intravenously in patients with chronic kidney disease who are receiving hemodialysis.</p> <p>In August 2015, Amgen submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etelcalcetide to seek approval for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on hemodialysis.</p> <p>In September 2015, Amgen submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etelcalcetide to seek approval for the treatment of SHPT in adult patients with CKD on hemodialysis.</p>
IMLYGIC™ (talimogene laherparepvec) <i>tal im" oh jeen la her" pa rep" vek</i>	Oncolytic Immunotherapy	Hematology/Oncology	<p>IMLYGIC™ is an oncolytic immunotherapy derived from HSV-1.</p> <p>A trial to evaluate talimogene laherparepvec in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with mid- to late-stage metastatic melanoma is ongoing.</p>

* Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
 ‡Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of November 2, 2015. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

PHASE THREE

Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
Kyprolis® (carfilzomib) <i>car fil' zoe mib</i>	Small Molecule	Hematology/ Oncology	<p>Kyprolis® is a proteasome inhibitor.</p> <p>Amgen has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Kyprolis® to seek approval for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy based on the data from the global Phase 3 ASPIRE (Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone for the treatment of Patients with Relapsed Multiple Myeloma) trial.</p> <p>In September 2015, the U.S. Food and Drug Administration (FDA) accepted for priority review the supplemental New Drug Application of Kyprolis® for Injection for patients with relapsed multiple myeloma based on data from the ENDEAVOR (Randomized, Open Label, Phase 3 Study of Carfilzomib Plus Dexamethasone Vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma) trial. The FDA has set a January 22, 2016 Prescription Drug User Fee Act (PDUFA) target action date as a goal for the completion of their review of our application.</p> <p>A Phase 3 study, CLARION, evaluating Kyprolis® in combination with melphalan and prednisone compared to bortezomib, melphalan and prednisone in newly diagnosed multiple myeloma is ongoing. A Phase 3 study, ARROW, with weekly dosing in relapsed and refractory multiple myeloma is also underway.</p>
Prolia® (denosumab) <i>den oh sue' mab</i>	Monoclonal Antibody	Bone Health	<p>Denosumab is a human monoclonal antibody that inhibits RANKL.</p> <p>A Phase 3 study of Prolia® for the treatment of glucocorticoid-induced osteoporosis is ongoing.</p>
Repatha® (evolocumab) <i>e" voe lok' ue mab</i>	Monoclonal Antibody	Cardiovascular	<p>Repatha® is a human monoclonal antibody that inhibits Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).</p> <p>Amgen has submitted an application seeking marketing approval of Repatha® for the treatment of high cholesterol to the Ministry of Health, Labour and Welfare in Japan.</p> <p>In September 2015, Amgen submitted an application to the U.S. Food and Drug Administration (FDA) for a single-dosing option for the monthly administration of Repatha® (evolocumab) Injection. The FDA has set a July 10, 2016 Prescription Drug User Fee Act (PDUFA) target action date as a goal for the completion of their review of our application.</p> <p>Additional Phase 3 studies to evaluate Repatha® for cardiovascular outcomes, on cognitive function, in statin-intolerant subjects, in subjects with genetic low-density lipoprotein disorders, and with intravascular ultrasound are ongoing.</p> <p>Repatha® is being developed in Japan by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.</p>
Romosozumab <i>roe" moe soz' ue mab</i>	Monoclonal Antibody	Bone Health	<p>Romosozumab is a humanized monoclonal antibody that inhibits the action of sclerostin. It is being investigated as a treatment for bone loss. Romosozumab is being developed in collaboration with UCB.</p> <p>Phase 3 studies for the treatment of postmenopausal women with osteoporosis and male osteoporosis are ongoing.</p>

* Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
 † Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of November 2, 2015. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

PHASE THREE

Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.

MOLECULE NAME & PRONUNCIATION	MODALITY	THERAPEUTIC AREA	DESCRIPTION
Trebananib <i>tre ban' a nib</i>	Peptibody	Hematology/ Oncology	Trebananib is a peptibody that inhibits Ang1 and Ang2. It is being investigated as a cancer treatment. In April 2015, Amgen announced that it has stopped administration of blinded investigational product in the Phase 3 study of trebananib in first-line ovarian cancer based on a recommendation by the Data Safety Monitoring Committee, who deemed the study unlikely to achieve its primary progression-free survival endpoint.
Vectibix® (panitumumab) <i>pan i tu mue' mab</i>	Monoclonal Antibody	Hematology/ Oncology	Vectibix® is a human monoclonal antibody antagonist of the epidermal growth factor receptor (EGFr). It is being investigated as a cancer treatment. A Phase 3 study evaluating the survival benefit of Vectibix® plus best supportive care (BSC) compared with BSC alone in subjects with chemorefractory, wild-type KRAS exon 2 mCRC is ongoing.
XGEVA® (denosumab) <i>den oh sue' mab</i>	Monoclonal Antibody	Hematology/ Oncology	Denosumab is a human monoclonal antibody that inhibits RANKL. Phase 3 studies of XGEVA® for the delay or prevention of bone metastases in patients with adjuvant breast cancer and prevention of skeletal-related events (SREs) in patients with multiple myeloma are ongoing. A Phase 2 study in non-small cell lung cancer is ongoing.

BIOSIMILARS†

A biosimilar, or follow-on biologic, is a biologic medicine designed to have active properties similar to one that has previously been licensed. Biosimilars follow a different regulatory review pathway than innovative products and indications.

MOLECULE NAME	MODALITY	THERAPEUTIC AREA	DESCRIPTION
ABP 215 (biosimilar bevacizumab)	Monoclonal Antibody	Hematology/ Oncology	ABP 215 (biosimilar bevacizumab) is an anti-vascular endothelial growth factor A (anti-VEGF) monoclonal antibody. The reference product primary conditions are colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, breast cancer and ovarian cancer.
ABP 494 (biosimilar cetuximab)	Monoclonal Antibody	Hematology/ Oncology	ABP 494 (biosimilar cetuximab) is an anti-epidermal growth factor receptor (anti-EGFr) monoclonal antibody. The reference product primary conditions are colorectal cancer and head and neck cancer.
ABP 501 (biosimilar adalimumab)	Monoclonal Antibody	Inflammation	ABP 501 (biosimilar adalimumab) is an anti-tumor necrosis factor-alpha (anti-TNF) monoclonal antibody. The reference product primary conditions are rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis.
ABP 710 (biosimilar infliximab)	Monoclonal Antibody	Inflammation	ABP 710 (biosimilar infliximab) is an anti-tumor necrosis factor-alpha (anti-TNF) monoclonal antibody. The reference product primary conditions are rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, psoriatic arthritis and ankylosing spondylitis.

* Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
† Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of November 2, 2015. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

BIOSIMILARS[‡] A biosimilar, or follow-on biologic, is a biologic medicine designed to have active properties similar to one that has previously been licensed. Biosimilars follow a different regulatory review pathway than innovative products and indications.

MOLECULE NAME	MODALITY	THERAPEUTIC AREA	DESCRIPTION
ABP 798 (biosimilar rituximab)	Monoclonal Antibody	Hematology/ Oncology & Inflammation	ABP 798 (biosimilar rituximab) is an anti-CD20 monoclonal antibody. The reference product primary conditions are non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.
ABP 980 (biosimilar trastuzumab)	Monoclonal Antibody	Hematology/ Oncology	ABP 980 (biosimilar trastuzumab) is an anti-HER2 monoclonal antibody. The reference product primary conditions are HER2+ breast cancer and HER2+ gastric cancer.

* Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
[‡]Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

This information reflects public disclosures current as of November 2, 2015. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.